EUVIMEDEUVIMED entdecken
Crossref

Investigating organic cation transporter 1 in drug interactions: New findings from in vitro and in vivo cynomolgus monkey studies

Ravindranath Reddy Gilibili, Simmi Gupta, Anup Arunrao Deshpande, Nian Tong, Dongyue Yu, Raghavendra Veerapuram, Prakash Subramanyam, Shruti Chitransh, Yazh Muthukumar, Kaushik Ghosh, Sagnik Chatterjee, Prakash Vachaspati und 3 weitere

Drug Metabolism and Disposition · 2026

DOI: 10.1016/j.dmd.2025.100220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Ravindranath Reddy Gilibili und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Candidate Optimization, Biocon Bristol Myers Squibb Research & Development Center (BBRC), Syngene International Ltd, Bangalore, India.…. Hauptthemen laut MEDLINE: Organic Cation Transporter 1. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Organic cation transporter 1 (OCT1, SLC22A1) is a key determinant in the hepatic disposition of cationic drugs, primarily supported by pharmacogenomic studies. However, evidence for OCT1-mediated drug-drug interactions (DDIs) remains limited. This study aimed to elucidate the role of OCT1 in DDIs using cynomolgus monkeys through comprehensive in vitro and in vivo experiments. Cynomolgus monkey OCT1 (cOCT1) shares 94.2% amino acid identity with human OCT1 (hOCT1). Transport assays in transfected human embryonic kidney 293 cells showed that sumatriptan, fenoterol, metformin, quinidine, and 1-methyl-4-phenylpyridinium were transported by cOCT1 at rates comparable to hOCT1 (less than 2-fold difference). The Km and Vmax values for cOCT1-mediated transport of sumatriptan and fenoterol were similar or within 2-fold to those of hOCT1 (Km: 188 ± 56 vs 178 ± 25 and 1.6 ± 0.48 vs 0.73 ± 0.47 μM, respectively, Vmax: 49.4 ± 8.3 vs 83.9 ± 5.2 and 124 ± 8.9 vs 158 ± 22 pmol/min per mg, respectively). Inhibition studies demonstrated that quinidine, rifamycin SV, and ketoprofen inhibited sumatriptan uptake in monkey hepatocytes to a similar extent as in human hepatocytes, with IC50 values within a 2- to 3-fold range. In addition, axitinib, nintedanib, and erlotinib were identified as inhibitors of both cOCT1 and hOCT1. In vivo, coadministration of axitinib (15 mg/kg), nintedanib (40 mg/kg), and erlotinib (15 mg/kg) increased sumatriptan area under the plasma concentration-time curve from zero to 24 hours by 1.3, 2.0, and 1.9-fold, respectively, compared with sumatriptan alone (2 mg/kg). These findings underscore the crucial role of OCT1 in the hepatic disposition and DDIs of cationic drugs, and indicate that cynomolgus monkeys may serve as a valuable model for studying OCT1-mediated drug disposition and interactions. SIGNIFICANCE STATEMENT: This study provides the first evidence that cynomolgus monkey organic cation transporter 1 (OCT1) transport and inhibition characteristics closely align with its human ortholog. Consistent with our in vitro findings, coadministration of OCT1 inhibitors (axitinib, nintedanib, and erlotinib) significantly increased the systemic exposure of sumatriptan in monkeys. These findings offer valuable insights into the role of OCT1 in drug-drug interactions and highlight the potential of cynomolgus monkeys as a useful and potentially translational model for OCT1-mediated disposition and interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organic Cation Transporter 1AnimalsMacaca fascicularisHumansDrug InteractionsHEK293 CellsMaleBiological TransportLiverHepatocytes

Stichwörter der Autor:innen

Cynomolgus monkeyDrug-drug interactionsOrganic cation transporter 1PharmacokineticsSumatriptan

Substanzen

Organic Cation Transporter 1

Autor:innen und Institutionen

  • Pharmaceutical Candidate Optimization, Biocon Bristol Myers Squibb Research & Development Center (BBRC), Syngene International Ltd, Bangalore, India. Electronic address: ravindra.reddy@syngeneintl.com.
  • Pharmaceutical Candidate Optimization, Biocon Bristol Myers Squibb Research & Development Center (BBRC), Syngene International Ltd, Bangalore, India.
  • Pharmaceutical Candidate Optimization, Development Drug Metabolism and Pharmacokinetics (DevDMPK), Bristol Myers Squibb, Princeton, New Jersey.
  • Pharmaceutical Candidate Optimization, Discovery Pharmaceutics and Analytical Sciences (DPAS), Bristol Myers Squibb, Princeton, New Jersey.
  • Leads Development and Optimization, Biocon Bristol Myers Squibb Research & Development Center (BBRC), Syngene International Ltd, Bangalore, India.
  • Leads Development and Optimization, Bristol Myers Squibb Company, Biocon Bristol Myers Squibb R&D Center, Bengaluru, Karnataka, India.

Zitieren

APA

Gilibili, R. R., Gupta, S., Deshpande, A. A., Tong, N., Yu, D., Veerapuram, R., Subramanyam, P., Chitransh, S., Muthukumar, Y., Ghosh, K., Chatterjee, S., Vachaspati, P., Mariappan, T. T., Soars, M. G., & Shen, H. (2026). Investigating organic cation transporter 1 in drug interactions: New findings from in vitro and in vivo cynomolgus monkey studies. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100220

Vancouver

Gilibili RR, Gupta S, Deshpande AA, Tong N, Yu D, Veerapuram R, et al. Investigating organic cation transporter 1 in drug interactions: New findings from in vitro and in vivo cynomolgus monkey studies. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2025.100220

BibTeX
@article{Gilibili2026,
  author = {Gilibili, Ravindranath Reddy and Gupta, Simmi and Deshpande, Anup Arunrao and Tong, Nian and Yu, Dongyue and Veerapuram, Raghavendra and Subramanyam, Prakash and Chitransh, Shruti and Muthukumar, Yazh and Ghosh, Kaushik and Chatterjee, Sagnik and Vachaspati, Prakash and Mariappan, T Thanga and Soars, Matthew G and Shen, Hong},
  title = {Investigating organic cation transporter 1 in drug interactions: New findings from in vitro and in vivo cynomolgus monkey studies},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  doi = {10.1016/j.dmd.2025.100220}
}
Kostenlos starten →